Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaGideon Bollag, K. B. Nolop, Prabha N. Ibrahim et al.|Nature|2010Cited by 1.8k
Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based ApproachBrian Higgins, Kathryn Packman|Clinical Cancer Research|2014Cited by 61